目的观察多发性骨髓瘤行低剂量沙利度胺联合常规化疗的疗效。方法选择2008年2月至2014年1月间收治的56例多发性骨髓瘤患者,随机分为观察组和对照组,每组28例。两组多发性骨髓瘤患者均采取常规化疗,观察组再联合低剂量沙利度胺。观察两组临床病理特征,监测患者的血常规、24 h尿蛋白、血清单克隆免疫球蛋白、骨骼X线平片情况,记录不良反应。结果观察组多发性骨髓瘤患者的总有效率为89.3%,高于对照组的64.3%(P=0.027);观察组患者的无进展生存时间、总生存期均长于对照组(P<0.001)。两组多发性骨髓瘤患者的治疗效果和预后情况差异有统计学意义(P<0.050)。结论对于多发性骨髓瘤的患者,采取低剂量沙利度胺联合常规化疗的方式,能够获得显著的治疗效果,保证较好的预后。 Objective To observe the efficacy of low-dose thalidomide combined with conventional chemotherapy in multiple myeloma. Methods 56 patients with multiple myeloma who were treated between February 2008 and January 2014 were randomly divided into observation group and control group with 28 cases in each group. Two groups of patients with multiple myeloma were routine chemotherapy, the observation group and then combined with low-dose thalidomide. The clinical and pathological features of the two groups were observed. The blood routine, 24 h urinary protein, serum monoclonal immunoglobulin, skeletal X-ray were observed and adverse reactions were recorded. Results The total effective rate of multiple myeloma patients in the observation group was 89.3%, which was higher than that in the control group (64.3%, P = 0.027). The progression-free survival and overall survival in the observation group were longer than those in the control group (P <0.001) . The therapeutic effect and prognosis of two groups of patients with multiple myeloma had statistical significance (P <0.050). Conclusions For patients with multiple myeloma, the low-dose thalidomide combined with conventional chemotherapy can achieve a significant therapeutic effect and ensure a good prognosis.